Skip to main content
main-content
Erschienen in: best practice onkologie 3/2022

02.03.2022 | Diagnostik in der Onkologie | CME-Topic

Routineuntersuchungen der Pathologie für die Therapie mit modernen Medikamenten

verfasst von: Prof. Dr. Korinna Jöhrens, Almuth Forberger, Pauline Wimberger, Josef Rüschoff

Erschienen in: best practice onkologie | Ausgabe 3/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Entwicklung der personalisierten Medizin und der Medikation mit Checkpointinhibitoren (CI) setzt ein gegenseitiges Verständnis zwischen den Onkologen und Pathologen voraus, wozu dieser Aufsatz beitragen soll. Es werden insbesondere für das Mammakarzinom und Endometriumkarzinom die Grundlagen der aktuellen Routinediagnostik mittels PD-L1 („programmed death ligand 1“), dMMR (Mismatch-Reparatur-Defizienz), MSI (Mikrosatelliteninstabilität), Polymerase-epsilon(POLE)-Mutation und p53-Mutation in der Pathologie anhand von Beispielen erklärt. Nicht nur die sorgsame Etablierung der Methoden mit geeigneten Kontrollen, sondern auch das Wissen über die korrekte Interpretation der Ergebnisse und deren mögliche Unterschiede in Abhängigkeit von Tumorentität und Therapie sind sowohl für Pathologen als auch für Gynäkoonkologen wichtig, um den PatientInnen eine bestmögliche Therapie anbieten zu können.
Literatur
1.
Zurück zum Zitat Hammond ME et al (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testingofestrogenand progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795 PubMedPubMedCentralCrossRef Hammond ME et al (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testingofestrogenand progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795 PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Nofech-Mozes S et al (2012) Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer. Clin Oncol 24:684–696 CrossRef Nofech-Mozes S et al (2012) Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer. Clin Oncol 24:684–696 CrossRef
3.
Zurück zum Zitat Curigliano G et al (2017) De-escalating and escalating treatments for earlystage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol 28:1700–1712 PubMedPubMedCentralCrossRef Curigliano G et al (2017) De-escalating and escalating treatments for earlystage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol 28:1700–1712 PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013 PubMedCrossRef Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013 PubMedCrossRef
6.
Zurück zum Zitat Wolff AC et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol 36:2105–2122 PubMedCrossRef Wolff AC et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol 36:2105–2122 PubMedCrossRef
7.
Zurück zum Zitat Jagosky M et al (2021) Combination of pertuzumab and trastuzumab in the treatment of HER2-positive early breast cancer: a review of the emerging clinical data. Breast Cancer 13:393–407 PubMedPubMedCentral Jagosky M et al (2021) Combination of pertuzumab and trastuzumab in the treatment of HER2-positive early breast cancer: a review of the emerging clinical data. Breast Cancer 13:393–407 PubMedPubMedCentral
8.
Zurück zum Zitat Petrelli F et al (2015) Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review andmeta-analysis of 64,196 patients. Breast Cancer Res Treat 153:477–491 PubMedCrossRef Petrelli F et al (2015) Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review andmeta-analysis of 64,196 patients. Breast Cancer Res Treat 153:477–491 PubMedCrossRef
9.
Zurück zum Zitat Mittendorf EA (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396(10257):1090–1100 PubMedCrossRef Mittendorf EA (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396(10257):1090–1100 PubMedCrossRef
10.
Zurück zum Zitat Cortes J et al (2020) Randomized doubleblind, phase lll study of penebrolizumab + chemotherapv versus placebo + cheitotherapv for previouslv untreated looallv recurrent inoperable or metastatic triple-negative breast cancer. JCD 38:1000 Cortes J et al (2020) Randomized doubleblind, phase lll study of penebrolizumab + chemotherapv versus placebo + cheitotherapv for previouslv untreated looallv recurrent inoperable or metastatic triple-negative breast cancer. JCD 38:1000
11.
Zurück zum Zitat Ho AY (2020) A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer 126(4):850–860 PubMedCrossRef Ho AY (2020) A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer 126(4):850–860 PubMedCrossRef
13.
Zurück zum Zitat Goldstein NS (2003) Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86–92 PubMedCrossRef Goldstein NS (2003) Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86–92 PubMedCrossRef
14.
15.
Zurück zum Zitat Schildhaus HU (2020) Immunhistochemie basierte prädiktive Biomarker bei Lungenkarzinomen. Pathologe 41:21–31 PubMedCrossRef Schildhaus HU (2020) Immunhistochemie basierte prädiktive Biomarker bei Lungenkarzinomen. Pathologe 41:21–31 PubMedCrossRef
16.
Zurück zum Zitat Pang JMB (2021) SP142 PD-L1 scoring shows high Interobserver and Intraobserver agreement in triple-negative breast carcinoma but overall low percentage agreement with other PD-L1 clones SP263 and 22C3. Am J Surg Pathol 45(8):1108–1117 PubMedPubMedCentralCrossRef Pang JMB (2021) SP142 PD-L1 scoring shows high Interobserver and Intraobserver agreement in triple-negative breast carcinoma but overall low percentage agreement with other PD-L1 clones SP263 and 22C3. Am J Surg Pathol 45(8):1108–1117 PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Reisenbichler ES (2020) Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Mod Pathol 33(9):1746–1752 PubMedPubMedCentralCrossRef Reisenbichler ES (2020) Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Mod Pathol 33(9):1746–1752 PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Bartels S (2018) CDKN2A loss and PIK3CA mutationin myoepithelial-like metaplastic breast cancer. J Pathol 245:373–383 PubMedCrossRef Bartels S (2018) CDKN2A loss and PIK3CA mutationin myoepithelial-like metaplastic breast cancer. J Pathol 245:373–383 PubMedCrossRef
20.
Zurück zum Zitat Kreipe HH (2021) Prädiktive Mutationsdiagnostik bei Mammakarzinomen. Pathologe 42:399–404 PubMedCrossRef Kreipe HH (2021) Prädiktive Mutationsdiagnostik bei Mammakarzinomen. Pathologe 42:399–404 PubMedCrossRef
21.
Zurück zum Zitat Tung NM (2020) TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 38:4274–4282 PubMedCrossRef Tung NM (2020) TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 38:4274–4282 PubMedCrossRef
22.
Zurück zum Zitat Parsons MT (2019) Large scale multifactorial likelihood quantitative analysis of BRCA1andBRCA2variants: an ENIGMA resource to support clinical variant classification. Hum Mutat 40:1557–1578 PubMedPubMedCentralCrossRef Parsons MT (2019) Large scale multifactorial likelihood quantitative analysis of BRCA1andBRCA2variants: an ENIGMA resource to support clinical variant classification. Hum Mutat 40:1557–1578 PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Pfarr N et al (2020) Testing NTRK testing: wet-lab and in silico comparison of RNA-based targeted sequencing assays. Genes Chromosomes Cancer 59:178–188 PubMedCrossRef Pfarr N et al (2020) Testing NTRK testing: wet-lab and in silico comparison of RNA-based targeted sequencing assays. Genes Chromosomes Cancer 59:178–188 PubMedCrossRef
25.
Zurück zum Zitat Haunschild CE et al (2021) The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecol Oncol 160(1):333–345 PubMedCrossRef Haunschild CE et al (2021) The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecol Oncol 160(1):333–345 PubMedCrossRef
26.
Zurück zum Zitat Concin N et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39 PubMedCrossRef Concin N et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39 PubMedCrossRef
27.
Zurück zum Zitat Casey L (2021) POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP companion society session at the USCAP 2020 annual meeting. Int J Gynecol Pathol 40:5–16 PubMedCrossRef Casey L (2021) POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP companion society session at the USCAP 2020 annual meeting. Int J Gynecol Pathol 40:5–16 PubMedCrossRef
28.
Zurück zum Zitat Rhiem K (2021) Hereditäres Endometriumkarzinom Plädoyer für Genanalysen in der Regelversorgung. Dtsch Arztebl 1:32–36 Rhiem K (2021) Hereditäres Endometriumkarzinom Plädoyer für Genanalysen in der Regelversorgung. Dtsch Arztebl 1:32–36
29.
Zurück zum Zitat Bosse T (2020) WHO classification female genital tumours. WHO, IARC, , S 252–255 Bosse T (2020) WHO classification female genital tumours. WHO, IARC, , S 252–255
30.
Zurück zum Zitat Diebold J (2021) Was ist neu in der WHO-Klassifikation 2020? SZO, , S 6–11 Diebold J (2021) Was ist neu in der WHO-Klassifikation 2020? SZO, , S 6–11
33.
Zurück zum Zitat Jöhrens K (2021) Qualitätssicherung in der dMMR- und MSI-Diagnostik. Pathologe 42(4):405–413 PubMedCrossRef Jöhrens K (2021) Qualitätssicherung in der dMMR- und MSI-Diagnostik. Pathologe 42(4):405–413 PubMedCrossRef
34.
Zurück zum Zitat Stelloo E (2017) Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol 28:96–102 PubMedCrossRef Stelloo E (2017) Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol 28:96–102 PubMedCrossRef
35.
Zurück zum Zitat Siemanowski J (2021) Managing difficulties of microsatellite instability testing in endometrial cancer-limitations and advantages of four different PCR based approaches. Cancers 13(6):1268 PubMedPubMedCentralCrossRef Siemanowski J (2021) Managing difficulties of microsatellite instability testing in endometrial cancer-limitations and advantages of four different PCR based approaches. Cancers 13(6):1268 PubMedPubMedCentralCrossRef
36.
39.
Zurück zum Zitat Lee CH et al (2021) Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 22(7):946–958 PubMedCrossRef Lee CH et al (2021) Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 22(7):946–958 PubMedCrossRef
Metadaten
Titel
Routineuntersuchungen der Pathologie für die Therapie mit modernen Medikamenten
verfasst von
Prof. Dr. Korinna Jöhrens
Almuth Forberger
Pauline Wimberger
Josef Rüschoff
Publikationsdatum
02.03.2022